ZNTL Zentalis Pharmaceuticals Inc.

42.04
+1.63  (+4%)
Previous Close 40.41
Open 40.44
52 Week Low 22
52 Week High 61.29
Market Cap $1,707,406,548
Shares 40,613,857
Float 16,136,645
Enterprise Value $1,100,813,653
Volume 249,703
Av. Daily Volume 396,350
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ZN-c3
Solid tumors
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
ZN-e4
Non-small cell lung cancer
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
ZN-c5 and abemaciclib
ER+/HER2- advanced breast cancer
Phase 1b
Phase 1b
Phase 1b trial initiation announced January 6, 2021.
ZN-d5
Acute Myeloid Leukemia
Phase 1
Phase 1
Phase 1 trial initiation announced January 6, 2021.
ZN-c3 and chemotherapy
Ovarian cancer
Phase 1
Phase 1
Phase 1 trial initiation announced January 6, 2021.
ZN-c5
ER+/HER2- breast cancer
Phase 1/2
Phase 1/2
Phase 2 monotherapy trial to be initiated in the first half of 2021.

Latest News

  1. NEW YORK and SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) today announced a strategic collaboration with Tempus to leverage the company's patient-derived organoid biological modeling platform to strengthen Zentalis' discovery and research capabilities.

    Zentalis CEO Anthony Sun commented, "We are thrilled to be entering into this collaboration with Tempus and its unique platform to help us discover and develop novel therapies aimed at a variety of cancers. This partnership provides Zentalis with access to Tempus' one-of-a-kind resource to help validate our mechanistic discoveries, beginning with our WEE1 inhibitor, and ultimately to expand our growing product pipeline."

    Tempus' proprietary platform…

    NEW YORK and SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) today announced a strategic collaboration with Tempus to leverage the company's patient-derived organoid biological modeling platform to strengthen Zentalis' discovery and research capabilities.

    Zentalis CEO Anthony Sun commented, "We are thrilled to be entering into this collaboration with Tempus and its unique platform to help us discover and develop novel therapies aimed at a variety of cancers. This partnership provides Zentalis with access to Tempus' one-of-a-kind resource to help validate our mechanistic discoveries, beginning with our WEE1 inhibitor, and ultimately to expand our growing product pipeline."

    Tempus' proprietary platform has the ability to grow and recapitulate tumors both genetically and functionally, some of which can be used for DNA repair profiling and research on potential therapeutic sensitivity. In harnessing Tempus' cutting-edge approach, the collaboration will initially aim to validate Zentalis' WEE1 inhibitor, ZN-c3, and its DNA damage response pathway in genetically distinct patient populations. The platform will also be used to investigate additional novel targets of cancer pathways that may be identified by Zentalis, as well as support the study of Zentalis' current product candidates across various indications.

    "We believe that our library of patient-derived organoids is well positioned to better identify patient populations that could benefit from Zentalis' WEE1 inhibitor, ZN-c3," said Marc Yoskowitz, Chief Strategy Officer of Tempus. "We look forward to applying the full potential of our platform to address the ever-increasing unmet needs of cancer patients."

    Zentalis retains full ownership of its therapeutic candidates.

    About ZN-c3

    ZN-c3 is an oral inhibitor of WEE1 in development for the treatment of advanced solid tumors. The inhibition of WEE1, a DNA damage response protein, aims to generate sufficient DNA damage in cancer cells, causing cell death, thereby preventing tumor growth and potentially causing tumor regression. Zentalis is currently conducting a Phase 1/2 clinical trial in patients with advanced solid tumors and expects to report data from the Phase 1 portion at the AACR Annual Meeting 2021. In addition, the Company is also conducting a Phase 1b trial evaluating ZN-c3 in combination with chemotherapy in patients with advanced ovarian cancer, with plans to initiate a Phase 2 trial investigating ZN-c3 as a monotherapy in patients with uterine serous carcinoma in 2021.

    About Zentalis  

    Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.

    For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the development, potential, safety, efficacy, and regulatory and clinical progress of our product candidates in the Unites States and globally, plans and timing for the initiation of and the release of data from our clinical trials and our ability to meet other key milestones, and activities in connection with our collaboration with Tempus. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the outbreak of the novel coronavirus disease, COVID-19, has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials; our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of our lead product candidate; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel; and significant costs as a result of operating as a public company. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 filed with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    Investor Contact:

    Thomas Hoffmann

    Solebury Trout

    1.646.378.2931



    Media Contact:

    Julia Deutsch

    Solebury Trout

    1.646.378.2967



    Primary Logo

    View Full Article Hide Full Article
  2. NEW YORK and SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that initial clinical data from the Phase 1 portion of its Phase 1/2 monotherapy trial of ZN-c3, the Company's WEE1 inhibitor, in advanced solid tumors has been selected for presentation at the upcoming virtual American Association for Cancer Research (AACR) Annual Meeting 2021. AACR is being held April 10-15 and May 17-21.

    About ZN-c3

    ZN-c3 is an oral inhibitor of WEE1 in development for the treatment of advanced solid tumors. The inhibition of WEE1, a DNA damage…

    NEW YORK and SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that initial clinical data from the Phase 1 portion of its Phase 1/2 monotherapy trial of ZN-c3, the Company's WEE1 inhibitor, in advanced solid tumors has been selected for presentation at the upcoming virtual American Association for Cancer Research (AACR) Annual Meeting 2021. AACR is being held April 10-15 and May 17-21.

    About ZN-c3

    ZN-c3 is an oral inhibitor of WEE1 in development for the treatment of advanced solid tumors. The inhibition of WEE1, a DNA damage response protein, aims to generate sufficient DNA damage in cancer cells, causing cell death, thereby preventing tumor growth and potentially causing tumor regression. Zentalis is currently conducting a Phase 1/2 clinical trial in patients with advanced solid tumors and expects to report data from the Phase 1 portion at the AACR Annual Meeting 2021. In addition, the Company is also conducting a Phase 1b trial evaluating ZN-c3 in combination with chemotherapy in patients with advanced ovarian cancer, with plans to initiate a Phase 2 trial investigating ZN-c3 as a monotherapy in patients with uterine serous carcinoma in 2021.

    About Zentalis

    Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.

    For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the development, potential, safety, efficacy, and regulatory and clinical progress of our product candidates in the Unites States and globally, plans and timing for the initiation of and the release of data from our clinical trials, including the presentation of initial clinical data from the Phase 1 portion of our Phase 1/2 clinical trial of ZN-c3 at AACR Annual Meeting 2021, and our ability to meet other key milestones, the anticipated direct and indirect impact of COVID-19 on our business and operations, and the sufficiency of our cash and cash equivalents. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the outbreak of the novel coronavirus disease, COVID-19, has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials; our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of our lead product candidate; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel; and significant costs as a result of operating as a public company. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 filed with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    Investor Contact:

    Thomas Hoffmann

    Solebury Trout

    1.646.378.2931

    Media Contact:

    Julia Deutsch

    Solebury Trout

    1.646.378.2967



    Primary Logo

    View Full Article Hide Full Article
  3. NEW YORK & SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Enoch Kariuki, PharmD, to its Board of Directors. Dr. Kariuki is a highly accomplished finance executive, bringing over a decade of deep expertise in life sciences investment banking, strategic advising and business development to Zentalis.

    "We are pleased to welcome Enoch to our Board of Directors, and believe his experience as a financial leader in the healthcare sector will offer invaluable perspective for our growing organization," said Dr…

    NEW YORK & SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Enoch Kariuki, PharmD, to its Board of Directors. Dr. Kariuki is a highly accomplished finance executive, bringing over a decade of deep expertise in life sciences investment banking, strategic advising and business development to Zentalis.

    "We are pleased to welcome Enoch to our Board of Directors, and believe his experience as a financial leader in the healthcare sector will offer invaluable perspective for our growing organization," said Dr. Anthony Sun, Chairman and Chief Executive Officer at Zentalis Pharmaceuticals. "Over the course of his career, Enoch has played a pivotal role in follow-on offerings and multibillion-dollar mergers and acquisitions, and we look forward to applying his guidance and learnings to Zentalis' corporate financial strategy."

    Dr. Kariuki most recently served as Chief Financial Officer at VelosBio, a clinical-stage oncology-focused biopharmaceutical company, which was acquired by Merck. At VelosBio, he led all finance-related and investor relations functions. Prior to VelosBio, he served as Senior Vice President of Corporate Development at Synthorx. During his tenure, he led the company's IPO as well as business development efforts leading up to its acquisition by Sanofi. Previously, Dr. Kariuki was Vice President at H.I.G. Capital, where he invested in and served on the boards of multiple life sciences companies. Earlier in his career, Dr. Kariuki held various roles in investment banking at Leerink Partners and UBS Investment Bank.

    He completed a Post-Doctoral Fellowship in R&D Strategy and Analytics at Bristol Myers Squibb and was a Pharmacist at CVS Caremark. Dr. Kariuki received an MBA from the Tuck School of Business at Dartmouth College and a PharmD from Texas Southern University.

    "I am honored to join Zentalis' Board and to serve as the Chair of the Audit Committee," commented Enoch Kariuki, PharmD. "I am eager to work closely with the Zentalis team to provide collaborative and meaningful contributions as they navigate bringing potentially differentiated cancer therapeutics to patients."

    About Zentalis

    Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.

    For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding Dr. Kariuki's expected contributions to our board, our growth strategy and our expectations surrounding the development, potential, safety, efficacy, and regulatory and clinical progress of our product candidates in the Unites States and globally. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the outbreak of the novel coronavirus disease, COVID-19, has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials; our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of our lead product candidate; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel; and significant costs as a result of operating as a public company. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 filed with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    Investor Contact:

    Thomas Hoffmann

    Solebury Trout

    1.646.378.2931

    Media Contact:

    Julia Deutsch

    Solebury Trout

    1.646.378.2967



    Primary Logo

    View Full Article Hide Full Article
  4. NEW YORK and SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming virtual investor conferences.

    Presentation Details:

    Event: Guggenheim Healthcare Talks 2021 Oncology Days
    Date: Friday, February 12, 2021
    Time: 1:30 p.m. EST

    Event: SVB Leerink 10th Annual Global Healthcare Conference
    Date: Wednesday, February 24, 2021
    Time: 10:00 a.m. EST

    Live webcasts from the Guggenheim and SVB Leerink fireside chats will…

    NEW YORK and SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming virtual investor conferences.

    Presentation Details:

    Event: Guggenheim Healthcare Talks 2021 Oncology Days

    Date: Friday, February 12, 2021

    Time: 1:30 p.m. EST

    Event: SVB Leerink 10th Annual Global Healthcare Conference

    Date: Wednesday, February 24, 2021

    Time: 10:00 a.m. EST

    Live webcasts from the Guggenheim and SVB Leerink fireside chats will be accessible through the Investors section of the Company's website at www.zentalis.com. Following the events, archived webcasts will be available on the Zentalis website.

    About Zentalis

    Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.

    For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

    Investor Contact:

    Thomas Hoffmann

    Solebury Trout

    1.646.378.2931

    Media Contact:

    Julia Deutsch

    Solebury Trout

    1.646.378.2967



    Primary Logo

    View Full Article Hide Full Article
  5. NEW YORK and SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Zentalis has initiated patient dosing in three new combination and monotherapy clinical trials:

    • A Phase 1b combination trial with ZN-c5 and abemaciclib (marketed as Verzenio® by Eli Lilly) in ER+/HER2- advanced breast cancer;
    • A Phase 1 combination dose escalation trial with ZN-c3 and chemotherapy in advanced ovarian cancer; and
    • A Phase 1 trial with ZN-d5 in acute myeloid leukemia and Non-Hodgkin's Lymphoma.

    "At Zentalis, our primary focus is to rapidly bring…

    NEW YORK and SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Zentalis has initiated patient dosing in three new combination and monotherapy clinical trials:

    • A Phase 1b combination trial with ZN-c5 and abemaciclib (marketed as Verzenio® by Eli Lilly) in ER+/HER2- advanced breast cancer;
    • A Phase 1 combination dose escalation trial with ZN-c3 and chemotherapy in advanced ovarian cancer; and
    • A Phase 1 trial with ZN-d5 in acute myeloid leukemia and Non-Hodgkin's Lymphoma.

    "At Zentalis, our primary focus is to rapidly bring novel and transformative medicines to patients diagnosed with a wide variety of cancers," said Dr. Anthony Sun, Chairman and Chief Executive Officer at Zentalis Pharmaceuticals. "With the initiation of these clinical trials during the fourth quarter of 2020, we are excited to explore the potential benefit of our candidates, either as a monotherapy or in combination, assessing the safety, tolerability and pharmacokinetics of the treatments. These data will provide key insight needed for future trials, laying the foundation to continue to advance the investigation of ZN-c5, ZN-c3 and ZN-d5."   

    For more information on the trials, visit www.clinicaltrials.gov.

    About ZN-c5

    ZN-c5 is an oral selective estrogen receptor degrader (SERD) being developed for the treatment of ER+/HER2- advanced or metastatic breast cancer. This form of breast cancer is reliant on the estrogen receptor for tumor growth and survival. Zentalis is currently conducting a Phase 1/2 clinical trial of ZN-c5 in patients with ER+/HER2- advanced or metastatic breast cancer as a monotherapy. The Company is also investigating ZN-c5 in combination studies, including a Phase 1/2 trial with palbociclib (Ibrance®) through a clinical research collaboration with Pfizer and a Phase 1b trial with abemaciclib (Verzenio®) through a clinical research collaboration with Eli Lilly.

    About ZN-c3

    ZN-c3 is an oral inhibitor of WEE1 in development for the treatment of advanced solid tumors. The inhibition of WEE1, a DNA damage response protein, aims to generate sufficient DNA damage in cancer cells, causing cell death, thereby preventing tumor growth and potentially causing tumor regression. Zentalis is currently conducting a Phase 1/2 clinical trial of ZN-c3 as a monotherapy in patients with advanced solid tumors, and a Phase 1b clinical trial evaluating ZN-c3 in combination with chemotherapy in patients with advanced ovarian cancer.

    About ZN-d5

    ZN-d5 is an oral inhibitor of B-cell lymphoma 2 (BCL-2), in development initially for the treatment of hematologic malignancies. BCL-2 plays a critical role in the regulation of cell death and the overexpression of this protein is frequently detected in numerous cancer types, preventing apoptosis. Zentalis believes a BCL-2 inhibitor will restore the normal apoptosis process. The Company has initiated a Phase 1 trial of ZN-d5 in patients with AML and Non-Hodgkin's Lymphoma.

    About Zentalis

    Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.

    For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the development, potential, safety, efficacy, and regulatory and clinical progress of our product candidates in the Unites States and globally, plans and timing of clinical trials and our ability to meet other key milestones. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the outbreak of the novel coronavirus disease, COVID-19, has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials; our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of our lead product candidate; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel; and significant costs as a result of operating as a public company. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 filed with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    Investor Contact:

    Thomas Hoffmann

    Solebury Trout

    1.646.378.2931

    Media Contact:

    Julia Deutsch

    Solebury Trout

    1.646.378.2967

     



    Primary Logo

    View Full Article Hide Full Article
View All Zentalis Pharmaceuticals Inc. News